isabelobrien, Author at European Medical Journal - Page 17 of 68

Social media interaction icons

Social media key to Gen Z pharma hires, says ABPI

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Rafael Fonseca

Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

Rafael Fonseca, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA

GSK’s Dheepa Chari on the evolving sphere of scientific communication

Dheepa Chari joins EMJ GOLD to discuss her career path, AI in pharma and the future of scientific communication.

Illustration of kidneys

Vantive to invest $1bn in digital kidney care therapies

Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.

Two men walking on arrows

Sanofi to acquire Blueprint in $9.1bn deal

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

Two illustrated hands, one holding money, the other a first aid box

King’s Fund sheds light on access to medicine in UK

The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.

Stack of cartoon money

Kyron.bio lands €5.5m to refine biologic drug design

The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.

The word spotlight on a blue background

Spotlight: May 2025

Catch up on May’s key pharma news, research updates and policy shifts.

Bradley Monk

Onc Now: Episode 18: What's New from ESGO 2025?

Bradley Monk, Medical Director of Late-Phase Research at Florida Cancer Specialists, shares his insights from ESGO 2025 and landmark studies in gynaecologic oncology.

Paolo Gallipoli

Hema Now: Episode 17: What Drives Change in Leukaemia Cells?

Paolo Gallipoli, Clinical Reader, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London joins the podcast to discuss the biology, onset, and treatment of myeloid leukaemias.